

Marketing anti-TB drugs without price approval by Warner Hindustan

1555. SHRI RAJNI RANJAN SAHU:

Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 19 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) since when Warner Hindustan is marketing Anti TB medicines without price approval and when did it come to Government's notice;

(b) what was the sales turn over of these products from the inception of price control order, 1979 per year;

(c) whether Government worked out the total overcharging by the company on these products and if so, what is the total amount accumulated from 1979 upto 31st October 1985;

(d) why penal action has not been taken against the company so far despite the fact that Government are fully armed with adequate power under provision 29 of Drugs Price Control Order, 1979 for violation of provision;

(e) whether it is a fact that apart from overcharging the company is producing these products without any authority; and

(f) if so, what are the reasons for delay in action?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) M/s. WARNER Hindustan Limited started marketing Isokin 300 tablets at a price higher than the Government approved price in 1982 and also introduced Isokin Liquid 100ml bottle without price approval in the same year. They treated both these products as Category IV products. This fact came to the Government's notice in early 1984.

(b) and (c) Details of sales turn-over and the magnitude of total overcharged amount have not been compiled.

(d) and (f) Information has already been furnished in reply to Rajya Sabha Unstarred Question No. 189 answered on 18th November, 1985.

(e) The company is producing Isokin Liquid and Isokin 300 tablets under authorisation of doubtful validity.

Overcharging of drug prices

1556. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 160 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that number of instances came to Government's notice for overcharging the prices, marketing without price approval and making huge unintended benefits by the drug formulators;

(b) whether it is a fact that prices of medicines would have come down considerably, if the provisions of Price Control Order had been implemented;

(c) whether it is also a fact that the drug industry made around fifteen hundred crores unintended benefits from the inception of price control order;

(d) whether Government have worked out the figures if so, what are the details therefor; and

(e) by when the action for violation of provisions by drug's companies will be finally-taken and unit ended amounted collected?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) The implementation of the Drugs (Prices Control) Order to the extent possible has helped to moderate the price of medicines.

(c) and (d) No, Sir. Action to quantify the excess amount recoverable under the DPCO 1979 is being taken.

(e) Action against the various manufacturers is already on in accordance with the due process of law.

Violation of Drug Price Control Order

SHRI (MOLANA) ASRARUL HAQ: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 163 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) what are the names of drug companies whose instances of marketing formulations at higher than fixed prices, marketing medicines without price approval, amount due under Drugs Equalisation Fund Account and wrong categorisation of formulations came to Government's notice along with full details in respect of name of each formulation, composition and price charged from the consumers;

(b) what are the names of the companies against whom action under provision 29 of Drug Price Control Order, 1979 was taken along with full details;

(c) what are the names of the companies whose cases are still pending and by when the action will be finalised; and

(d) when was each case came to Government's notice and what are the reasons for the delay?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Information to the extent available is given in the attached statement (See below).

(b) to (d) Action in all these cases is on in accordance with the due procedure of Law.

Statement

Sl. No.	Name of the Company
---------	---------------------

(a) Marketing without price approval after crossing the limit of Rs. 50 lakhs in sales turnover.

1. M/s. Concept Pharmaceuticals.
2. M/s. Lord's Pharmaceuticals.

3. M/s. Gratus Pharma.
4. M/s. Glemark Pharmaceuticals Pvt. Ltd.
5. M/s. Martin Pharmaceuticals.
6. M/s. Sidmark Labs. (I) Pvt. Ltd.
7. M/s. Julabs.
8. M/s. Mexin Medicament (P) Ltd.
9. M/s. Dyanamic Pharmaceuticals Pvt. Ltd.
10. M/s. Comteek Labs.
11. M/s. Calfax Labs. (P) Ltd.
12. M/s. Martidare Pharmaceuticals.
13. M/s. Novochem Labs. Pvt. Ltd.
14. M/s. Pfimex International.
15. M/s. Pfimex International.
16. M/s. Imkenex India Ltd.
17. M/s. Bio Vaccines Pvt. Ltd.
18. M/s. Citadel Fine Pharmaceuticals (P) Ltd.
19. M/s. Indochem Labs. Pvt. Ltd.
20. M/s. Sunways (I) Ltd.
21. M/s. Associated Labs. (P) Ltd.
22. M/s. Standard Organics Ltd.
23. M/s. Ajanta Pharma Pvt. Ltd.
24. M/s. Smith & Nephew (I) Ltd.
25. M/s. Pharmaton.
26. M/s. Robepharm (India) Pvt. Ltd.
27. M/s. Pharma Research & Analytical Labs.
28. M/s. Indian Medicine Division.
29. M/s. Health Aids Ltd.
30. M/s. Abhishek Pharma.
31. M/s. Eclat & Jal Pvt. Ltd.
32. M/s. Ayerst Labs. and M/s. Whitehall Labs.
33. M/s. UNI-UCB Ltd.
34. M/s. Boehringer Knoll Ltd.
35. M/s. Geno Pharmaceuticals Ltd.
36. M/s. Mosmochem Pvt. Ltd.
37. M/s. Ceevee Pharma Pvt. Ltd.
38. M/s. Cadila Chemicals Pvt. Ltd.
39. M/s. German Remedies Ltd.